GTA: Glyceryltriacetate
Phase 1Small molecule
GTA: Glyceryltriacetate is one of 3 small molecule programs targeting Canavan disease. It is currently in Phase 1.
1
Indications
1
Total Trials
0
Active Trials
2
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
5 competitors in Canavan Disease
#DrugCompanyPhaseTrials
1Keppra
UCBPhase 1
Rayos
RRoxane Laboratories
Phase 1
GTA: Glyceryltriacetate
SSheba Medical Center
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for GTA: Glyceryltriacetate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- SSheba Medical Center